The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of Latino ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC).
 
Regina Barragán Carrillo
No Relationships to Disclose
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Luis A Meza
No Relationships to Disclose
 
Paulo Gustavo Bergerot
No Relationships to Disclose
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; Janssen Oncology; Sanofi/Aventis
Research Funding - Pfizer (Inst)
 
Joann Hsu
No Relationships to Disclose
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Nicholas Salgia
No Relationships to Disclose
 
Alex Chehrazi-Raffle
Honoraria - ASCO; Medical Oncology Association of Southern California; OncLive/MJH Life Sciences
Consulting or Advisory Role - Aveo Inc; Exelixis; Seagen
Speakers' Bureau - Exelixis
Research Funding - Exelixis
Travel, Accommodations, Expenses - Bayer
 
Abhishek Tripathi
Consulting or Advisory Role - AADi; Bayer; Deka Biosciences; Exelixis; Gilead Sciences; Seattle Genetics/Astellas
Speakers' Bureau - Sanofi
Research Funding - Aravive (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst)
 
Daniela V. Castro
No Relationships to Disclose
 
Benjamin Mercier
No Relationships to Disclose
 
Gregory Caporaso
No Relationships to Disclose
 
Keehoon Lee
No Relationships to Disclose
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen